Table 4. Molecular analyses of the 40 treated patients treated on Phase I trials.
Molecular mutation or aberration | Number of patients tested | Number of patients with a mutation or aberration |
---|---|---|
KRAS | 11 | 2 |
NRAS | 7 | 0 |
BRAF | 10 | 0 |
CKIT | 3 | 0 |
EGFR | 10 | 0 |
PI3K | 9 | 0 |
GNAQ | 1 | 0 |
PTEN Loss | 3 | 0 |
ER IHC | 6 | 0 |
PR IHC | 6 | 0 |
HER-2/neu FISH | 8 | 1 |
Abbreviations: IHC immunohistochemistry; FISH fluorescence in situ hybridization